<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ900809-0099</DOCNO><DOCID>900809-0099.</DOCID><HL>   SmithKline Posts   Rise in Pretax Net   Of 6.5% for Period   ----   Special to The Wall Street Journal</HL><DATE>08/09/90</DATE><SO>WALL STREET JOURNAL (J), PAGE C9</SO><CO>   SBE</CO><IN>EARNINGS (ERN)DRUG MANUFACTURERS (DRG)</IN><LP>   LONDON -- SmithKline Beecham PLC, an Anglo-American healthand household products company, said it had a 6.5% rise insecond-quarter pretax profit, as the period's performance washighlighted by continued sales growth, strong trading profitsand significant debt reduction.   The two companies that merged in July 1989 to form thepresent concern were previously known as Beecham PLC of theU.K. and SmithKline Beckman Corp. of the U.S. The results arethe second set reported on a quarterly basis since themerger.</LP><TEXT>   At a news conference yesterday, Chief Executive Robert P.Bauman said he was &quot;delighted&quot; with the company'sperformance. He attributed the strong trading profit partlyto rising profit margins. &quot;That is the result of the merger,and the increased efficiencies we're getting,&quot; he said.   Unlike other executives in Britain who have reportedearnings recently, Mr. Bauman was fairly upbeat about hiscompany's prospects. &quot;We do plan to see continued earningsimprovement,&quot; he said.   In composite trading on the New York Stock Exchangeyesterday, SmithKline equity units (made up of five ordinaryshares plus one preferred share) closed at $46.875, up $3.50.   Year-earlier figures represent like-for-like comparisons,as if the merger had been in place in the second quarter of1989. A year-earlier dividend payment wasn't included in theresults.   Pretax profit rose to #197 million ($369.2 million) from#185 million in the second quarter of 1989. These figureswere at the top end of market expectations, which rangedbetween #175 million and #200 million.   Sales climbed 2.5% to #1.21 billion from #1.18 billion.Per-share earnings rose to 9.3 pence, up 2.2% from 9.1 pencein the corresponding year-earlier period.   Health and household products analyst Barbara Arzymanow ofKleinwort Benson Securities in London said the marketwelcomed SmithKline's earnings, which she said were betterthan widely expected.   Several SmithKline Beecham drugs posted strong salesgains. Sales of Augmentin, an antibiotic, rose 32% in thesecond quarter and 36% in the first half; sales of Engerix-B,the company's hepatitis-B vaccine, grew 75% in the secondquarter and 95% in the first half. Sales of Tagamet, theSmithKline Beecham anti-ulcer drug subject to increasingcompetition, rose 6% in the second quarter but slipped 1% inthe first half.   Roughly 45% of SmithKline Beecham's sales are in the U.S.,while Britain and continental Europe account for about 40%.Sales in Japan account for much of the remaining 15%.</TEXT></DOC>